Coherus Oncology Inc. (NASDAQ:CHRS) is one of the 10 best penny stocks that could triple your money.
On March 10, Coherus Oncology Inc. reported its fourth quarter EPS of (34c) above the street consensus of (31c), while revenue came in at $12.8 million versus $14.1 million expected.
Tonhom1009/Shutterstock.com
The company highlighted strong progress in 2025, including a significant increase in LOQTORZI sales and a major reduction in debt levels. Management emphasized its transition toward an oncology-focused business, supported by growing revenues, potential partnership opportunities, and a pipeline with multiple clinical catalysts expected in 2026. Commenting on the update, Coherus chairman and CEO, Denny Lanfear, stated:
“We are pleased with our progress in 2025, having doubled LOQTORZI sales while completing the transformation from a biosimilars company to an innovative oncology company focused on overcoming immune resistance in cancer. At the same time, we continued to reduce our overall debt since its peak in 2024 by over 90% to $38.8 million, we are now strategically positioned with growing revenues from our foundational PD-1 inhibitor, potential deal opportunities across the portfolio and geographies, and two promising pipeline candidates with multiple 2026 clinical readouts.”
Coherus Oncology Inc. is a commercial-stage company that develops immuno-oncology therapies to treat cancer. Its portfolio includes a commercial product, LOQTORZI, and pipeline candidates, including Casdozokitug and tagmokitug (CHS-114). It also has various agreements, including a collaboration agreement, license agreements, and out-licensing agreements with different companies.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.